Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review.

Autor:	Osmán-García I; Urology and Nephrology Department, Oncologic Urology Unit, University Hospital Virgen del Rocío, Seville, Spain, nachosman79@hotmail.com.; Biomedical Institute of Seville (IBiS), University Hospital Virgen del Rocío, CSIC, University of Seville, Seville, Spain, nachosman79@hotmail.com., Congregado-Ruiz CB; Urology and Nephrology Department, Oncologic Urology Unit, University Hospital Virgen del Rocío, Seville, Spain.; Biomedical Institute of Seville (IBiS), University Hospital Virgen del Rocío, CSIC, University of Seville, Seville, Spain., Lendínez-Cano G; Urology and Nephrology Department, Oncologic Urology Unit, University Hospital Virgen del Rocío, Seville, Spain., Baena-Villamarin C; Urology and Nephrology Department, Oncologic Urology Unit, University Hospital Virgen del Rocío, Seville, Spain., Conde-Sanchez JM; Urology and Nephrology Department, Oncologic Urology Unit, University Hospital Virgen del Rocío, Seville, Spain.; Biomedical Institute of Seville (IBiS), University Hospital Virgen del Rocío, CSIC, University of Seville, Seville, Spain., Medina-López RA; Urology and Nephrology Department, Oncologic Urology Unit, University Hospital Virgen del Rocío, Seville, Spain.; Biomedical Institute of Seville (IBiS), University Hospital Virgen del Rocío, CSIC, University of Seville, Seville, Spain.
Jazyk:	angličtina
Zdroj:	Urologia internationalis [Urol Int] 2020; Vol. 104 (3-4), pp. 323-326. Date of Electronic Publication: 2020 Jan 08.
DOI:	10.1159/000504515
Abstrakt:	Nivolumab is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody that selectively blocks the interaction between PD-1, which is expressed on activated T cells, and its ligands PD-L1 and PD-L2, which are expressed on immune cells and tumour cells. Patients with severe renal dysfunction and haemodialysis are not enrolled in clinical trials. However, in daily clinical practice, we have patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD). The scientific evidence about the efficacy and safety of nivolumab in these patients is scarce. We report three cases of mRCC patients with ESRD treated with second-line nivolumab therapy. They received both biweekly and monthly schemes. None of our patients showed grade 2-4 toxicities. Two patients achieved partial response and one progressive disease as best response. Our patients did not show increased toxicity by ESRD; also, two of the three patients had objectifiable clinical benefit. Nivolumab seems to be similarly safe for ESRD or dialysis patients as for patients without impaired kidney function (IKF). Dose adjustments might not be necessary. We suggest that patients on dialysis could be treated with nivolumab in the same way as populations without IKF. (© 2020 S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu